一、临床肿瘤杂志 (2023年第73卷第6期)

November/December 2023 - Volume 73 - Issue 6 (2023年11/12月第73卷第6期)
https://acsjournals.onlinelibrary.wiley.com/toc/15424863/2023/73/6

二、柳叶刀 (2023年第402卷第10413-10416期)

（一）04 November 2023 - Volume 402 - Issue 10413 (2023年11月4日第402卷第10413期)
https://www.thelancet.com/journals/lancet/issue/vol402no10413/PIIS0140-6736(23)X0044-0

COMMENT（评论）
1.每周胰岛素：1型糖尿病治疗的范式转变
(Weekly insulin: a paradigm shift in type 1 diabetes therapy)
作者：Amy S Shah* (Cincinnati Children's Hospital Medical Center, USA)

CORRESPONDENCE（通信）
2.神经激肽3受体拮抗剂fezolinetant的肿瘤风险
(Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant)
作者：Jonathan Douxfils* (Department of Pharmacy, Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Faculty of Medicine, University of Namur, France)

ARTICLES（文章）
3.秋水仙碱对胸外科大手术患者围手术期心房颤动和心肌损伤的影响（COP-AF）：一项国际随机试验
(Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial)
作者：David Conen* (Population Health Research Institute, Canada)
4.作为1型糖尿病患者基础-单次快注方案的一部分，每周注射一次的icodec胰岛素与每日注射一次的degludec胰岛素的比较(ONWARDS 6)：一项3a期、随机、开放标签、达标治疗试验
(Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial)
作者：David Russell-Jones (The Cedar Centre, Royal Surrey Foundation Trust, UK)
5.新生儿Fc受体抑制剂efgartigimod在成人原发免疫性血小板减少症中的疗效和安全性（ADVANCE IV）：一项多中心、随机、安慰剂对照的3期试验
(Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial)
作者：Catherine M Broome* (Lombardi Cancer Center, Division of Hematology, Georgetown University, USA)

注：新生儿Fc受体(FcRn)是一种组织相容性抗原-Ⅰ型同源FcRn，广泛分布于人体多种细胞，主要介导IgG再循环，延长IgG半衰期,维持其血浆浓度。
——摘自《新生儿Fc受体拮抗剂治疗全身型重症肌无力的现状和前景》，陈元懿，赵重波

CLINICAL PICTURE（临床表现）
6.奥美沙坦相关的sprue样肠病
(Olmesartan-associated sprue-like enteropathy)
作者：Laisa Socorro Briongos-Figuero* (Briongos-Figuero, Internal Medicine Service, Rio Hortega University Hospital, Spain)

（二）11 November 2023 - Volume 402 - Issue 10414 (2023年11月11日第402卷第10414期)
https://www.thelancet.com/journals/lancet/issue/vol402no10414/PIIS0140-6736(23)X0045-2

COMMENT（评论）
1.低剂量阿米替林治疗肠易激综合征：为初级保健做好准备？
(Low-dose amitriptyline in irritable bowel syndrome: ready for primary care?)
作者：Niek de Wit* (Julius Center for Health Sciences and Primary Care, Netherlands)

ARTICLES（文章）
2.甲氨蝶呤治疗伴滑膜炎的手骨关节炎（METHODS）：一项澳大利亚多中心、平行组、双盲、随机、安慰剂对照试验
(Methotrexate to treat hand osteoarthritis with synovitis (METHODS): an Australian, multisite, parallel-group, double-blind, randomised, placebo-controlled trial)
作者：Yuanyuan Wang, Flavia M Cicuttini* (School of Public Health and Preventive Medicine, Monash University, Australia)
3.低剂量阿米替林和滴定治疗肠易激综合征作为初级保健的二线治疗（ATLANTIS）：一项随机、双盲、安慰剂对照的3期试验
(Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial)
作者：Alexander C Ford* (Leeds Gastroenterology Institute, St James's University Hospital, UK)

VIEWPOINT（观点）
4.β阻滞剂转换为高血压的一线治疗
(β blockers switched to first-line therapy in hypertension)
作者：Franz H Messerli* (Faculty of Medicine, University of Bern, Switzerland)

（三）18 November 2023 - Volume 402 - Issue 10415 (2023年11月18日第402卷第10415期)
https://www.thelancet.com/journals/lancet/issue/vol402no10415/PIIS0140-6736(23)X0046-4

COMMENT（评论）
1.紫杉醇涂层球囊可安全用于治疗动脉狭窄
(Paclitaxel-coated balloons are safe for the treatment of arterial stenoses)
作者：Tuomas T Rissanen* (Heart Center, North Karelia Central Hospital, Finland)

CORRESPONDENCE（通信）
2.第二剂BA.5二价加强针后产生SARS-CoV-2 中和抗体
(SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster)
作者：Qian Wang, David D Ho* (Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, USA)
3.rocatinlimab治疗中至重度特应性皮炎的疗效
(Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis)
作者：Shivali Devjani, Jashin J Wu* (SUNY Downstate College of Medicine, USA; Department of Dermatology, University of Miami Miller School of Medicine, USA)
4.rocatinlimab治疗中至重度特应性皮炎的疗效——作者回复
(Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis – Authors' reply)
作者：Emma Guttman-Yassky* (Department of Dermatology and Department of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, USA)

ARTICLES（文章）
5.在切除或消融的高危肝细胞癌患者中，阿替利珠单抗联合贝伐珠单抗与主动监测的比较（IMbrave050）：一项随机、开放标签、多中心、3期试验
(Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial)
作者：Shukui Qin, Pierce K H Chow* (Jinling Hospital of Nanjing University of Chinese Medicine, China; National Cancer Centre Singapore, Singapore)
6.使用紫杉醇涂层装置进行股腘动脉介入手术的随机对照试验的死亡率：最新的患者水平的Meta分析
(Mortality in randomised controlled trials using paclitaxel-coated devices for femoropopliteal interventional procedures: an updated patient-level meta-analysis)
作者：Sahil A Parikh* (Columbia University Irving Medical Center, USA)

（四）25 November 2023 - Volume 402 - Issue 10416 (2023年11月25日第402卷第10416期)
https://www.thelancet.com/journals/lancet/issue/vol402no10416/PIIS0140-6736(23)X0048-8

ARTICLES（文章）
1.生物可降解聚合物西罗莫司洗脱支架与耐用聚合物依维莫司洗脱支架治疗ST段抬高型心肌梗死的长期结果比较：BIOSTEMI 随机优势试验的5年随访
(Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial)
作者：Juan F Iglesias* (Department of Cardiology, Geneva University Hospitals, Switzerland)
2.Zibotentan联合达格列净与达格列净在慢性肾脏病（ZENITH-CKD）患者中的比较：一项多中心、随机、活性药对照、2b期临床试验
(Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial)
作者：Hiddo J L Heerspink* (Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Netherlands)

三、新英格兰医学杂志 (2023年11月第389卷第18-21期)

（一）2 November 2023 - Volume 389 - No 18 (2023年11月2日第389卷第18期)
https://www.nejm.org/toc/nejm/389/18

ORIGINAL ARTICLES（原创文章）
1.沙利度胺治疗小肠血管发育不良引起的复发性出血
(Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia)
作者：Huimin Chen, Zhizheng Ge* (the Division of Gastroenterology and Hepatology, Shanghai Jiao-Tong University School of Medicine Renji Hospital, Shanghai Institute of Digestive Disease, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health (Shanghai Jiao-Tong University), China)
2.Durvalumab用于可切除的非小细胞肺癌的围手术期治疗
(Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer)
作者：John V. Heymach* (the Department of Thoracic–Head and Neck Medical Oncology, M.D. Anderson Cancer Center, USA)

（二）9 November 2023 - Volume 389 - No 19 (2023年11月9日第389卷第19期)
https://www.nejm.org/toc/nejm/389/19

ORIGINAL ARTICLES（原创文章）
1.肉毒杆菌毒素治疗孤立性或原发性头部震颤的试验
(Trial of Botulinum Toxin for Isolated or Essential Head Tremor)
作者：Ana Marques* (Service de Neurologie, Centre Expert Parkinson, France)
2.纳武利尤单抗联合吉西他滨-顺铂治疗晚期尿路上皮癌
(Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma)
作者：Michiel S. van der Heijden* (Department of Medical Oncology, Netherlands Cancer Institute, the Netherlands)
3.子宫内暴露于帕博利珠单抗后出现的严重免疫相关性肠炎
(Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab)
作者：Manuel A. Baarslag, Frédéric Amant* (Departments of Pediatrics, Amalia Children’s Hospital, the Netherlands; the Division of Gynecologic Oncology, Universitair Ziekenhuis Leuven, Belgium)

CORRESPONDENCE（通信）
4.超免疫球蛋白治疗先天性巨细胞病毒感染的随机试验——2年结局
(Randomized Trial of Hyperimmune Globulin for Congenital CMV Infection — 2-Year Outcomes)

（三）16 November 2023 - Volume 389 - No 20 (2023年11月16日第389卷第20期)
https://www.nejm.org/toc/nejm/389/20

ORIGINAL ARTICLES（原创文章）
1.Selpercatinib或化疗联合帕博利珠单抗一线治疗RET基因融合阳性非小细胞肺癌
(First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC)
作者：Caicun Zhou* (Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China)
2.塞普替尼 治疗晚期RET突变型甲状腺髓样癌的3期试验
(Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer)
作者：Julien Hadoux, Lori J. Wirth* (Service d’oncologie endocrinienne, département d’imagerie, Gustave Roussy and ENDOCAN-TUTHYREF Network, France; the Cancer Center, Massachusetts General Hospital, USA)
3.Gantenerumab 治疗早期阿尔茨海默病的两项 3 期试验
(Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease)
作者：Randall J. Bateman*, Janice Smith* (Department of Neurology, Washington University School of Medicine, UK; Roche Products, UK)

（四）23 November 2023 - Volume 389 - No 21 (2023年11月23日第389卷第21期)
https://www.nejm.org/toc/nejm/389/21

ORIGINAL ARTICLES（原创文章）
1.奥希替尼联合或不联合化疗治疗EGFR突变的晚期非小细胞肺癌
(Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC)
作者：David Planchard*, Pasi A. Jänne* (Department of Medical Oncology, Institut Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, France; Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana–Farber Cancer Institute, USA)
2.厄达替尼或化疗治疗晚期或转移性尿路上皮癌
(Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma)
作者：Yohann Loriot, Arlene O. Siefker-Radtke* ( Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, France; the University of Texas M.D. Anderson Cancer Center, USA)

CORRESPONDENCE（通信）
3.匹伐他汀与HIV中的心血管疾病
(Pitavastatin and Cardiovascular Disease in HIV)

四、美国医学会杂志 (2023年11月第330卷第17-20期)

（一）7 November 2023 -Volume 330 - No.17 (2023年11月7日第330卷第17期)
https://jamanetwork.com/journals/jama/issue/330/17

Original Investigation（原始调查）
1.替尔泊肽与基础胰岛素中添加赖脯胰岛素治疗2型糖尿病的对比：SURPASS-6随机临床试验
(Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial)
作者：Julio Rosenstock (Velocity Clinical Research at Medical City, USA)
2.兰地洛尔与感染性休克患者的器官衰竭：STRESS-L 随机临床试验
(Landiolol and Organ Failure in Patients With Septic Shock: The STRESS-L Randomized Clinical Trial)
作者：Tony Whitehouse (University Hospitals of Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, UK)
3.酒精使用障碍的药物治疗：一项系统评价和Meta分析
(Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis)
作者：Melissa McPheeters (RTI International–University of North Carolina at Chapel Hill Evidence-Based Practice Center, USA)

Editorial（社论）
4.β-受体阻滞剂在脓毒症患者中的应用：把拼图一块块地拼在一起
(β-Blockers in Patients With Sepsis: Putting the Puzzle Together, Piece by Piece)
作者：Steven M. Hollenberg (Emory University School of Medicine, USA)

Medical News in Brief（医学新闻简讯）
5.艾氯胺酮治疗难治性抑郁症比喹硫平更有效
(Esketamine More Effective Than Quetiapine for Hard-to-Treat Depression)
作者：Emily Harris

Comment & Response（评论与回应）
6.贝派地酸用于心血管事件的一级预防
(Bempedoic Acid for Primary Prevention of Cardiovascular Events)
作者：Mark R. Goldstein (Paoli, Pennsylvania)
7.贝派地酸用于心血管事件的一级预防——作者回复
(Bempedoic Acid for Primary Prevention of Cardiovascular Events—Reply)
作者：Steven E. Nissen (Cleveland Clinic Center for Clinical Research, USA)

（二）14 November 2023 -Volume 330 - No.18 (2023年11月14日第330卷第18期)
https://jamanetwork.com/journals/jama/issue/330/18

Original Investigation（原始调查）
1.静脉注射维生素C治疗COVID-19住院患者：两项协调随机临床试验
(Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials)
作者：Neill K. J. Adhikari*, François Lamontagne* (Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Canada; Faculty of Medicine and Health Sciences, Division of Internal Medicine, Université de Sherbrooke, Canada)

Research Letter（研究快报）
2.与胰高血糖素样肽-1受体激动剂减肥相关的胃肠道不良事件风险
(Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss)
作者：Mohit Sodhi (Faculty of Medicine, University of British Columbia, Canada)

Editorial（社论）
3.预防葡萄球菌感染的非定植策略：莫匹罗星的鼻子
(Decolonization Strategies to Prevent Staphylococcal Infections: Mupirocin by a Nose)
作者：Thomas R. Talbot (Vanderbilt University School of Medicine, USA)

Medical News in Brief（医学新闻简讯）
4. 在新发1型糖尿病患者中抗病毒药物可能保护的胰岛素
(Antivirals Might Preserve Insulin in New-Onset Type 1 Diabetes)
作者：Emily Harris

JAMA Patient Page（JAMA患者页面）
5.非处方纯孕激素口服避孕药
(Over-the-Counter Progestin-Only Oral Contraceptives)
作者：Erin Fleurant (Northwestern McGaw Medical Center, USA)

Comment & Response（评论与回应）
6.美罗培南在危重脓毒症患者中的应用
(Meropenem Administration in Critically Ill Patients With Sepsis)
作者：Ali Jabareen (Section of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, Israel)
7.美罗培南在危重脓毒症患者中的应用——作者回复
(Meropenem Administration in Critically Ill Patients With Sepsis—Reply)
作者：Giacomo Monti (Department of Anesthesia and Intensive Care, Vita-Salute San Raffaele University, Italy)
8.来特莫韦和缬更昔洛韦用于肾移植后巨细胞病毒预防的比较
(Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplant)
作者：Matthew B. Roberts (Infectious Diseases Unit, Royal Adelaide Hospital, Australia)
9.来特莫韦和缬更昔洛韦用于肾移植后巨细胞病毒预防的比较
(Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplant)
作者：Ilies Benotmane (Department of Nephrology, Dialysis, and Transplantation, Strasbourg University Hospital, France)
10.来特莫韦和缬更昔洛韦用于肾移植后巨细胞病毒预防的比较——作者回复
(Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplant—Reply)
作者：Ajit P. Limaye (University of Washington Medicine, USA)

（三）21 November 2023 -Volume 330 - No.19 (2023年11月21日第330卷第19期)
https://jamanetwork.com/journals/jama/issue/330/19

Medical News in Brief（医学新闻简讯）
1.美国国内首例耐多药的铜绿假单胞菌病例
(First US Domestic Case of Concerning Multidrug-Resistant P aeruginosa)
作者：Emily Harris
2.常见的他汀类药物似乎具有相似的疗效
(Common Statins Appear to Have Similar Effectiveness)
作者：Emily Harris
3.试验证实抗抑郁药可改善初级保健中的肠易激综合征（IBS）
(Trial Confirms Antidepressant Improves IBS in Primary Care)
作者：Emily Harris
4.单克隆抗体减缓1型糖尿病进展
(Monoclonal Antibody Slowed Type 1 Diabetes Progression)
作者：Emily Harris

Comment & Response（评论与回应）
5.抗生素治疗儿童急性鼻窦炎
(Antibiotics for Acute Sinusitis in Children)
作者：Jiahao Meng (Department of Orthopaedics, Xiangya Hospital, China)
6.抗生素治疗儿童急性鼻窦炎——作者回复
(Antibiotics for Acute Sinusitis in Children—Reply)
作者：Nader Shaikh (Division of General Academic Pediatrics, University of Pittsburgh School of Medicine, USA)

（四）28 November 2023 -Volume 330 - No.20 (2023年11月28日第330卷第20期)
https://jamanetwork.com/journals/jama/currentissue

Original Investigation（原始调查）
1.特瑞普利单抗联合化疗治疗复发或转移性鼻咽癌：JUPITER-02 随机临床试验
(Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma:The JUPITER-02 Randomized Clinical Trial)
作者：Hai-Qiang Mai (Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, China)

（医学新闻观点）
2.《胃肠病学周》亮点：新型治疗克罗恩病药物，重新定义肝病等
(Highlights From Gastroenterology Week: New Crohn Disease Drug, Redefining Liver Disease, and More)
作者：Melissa Suran
3.FDA将评估首个自行接种的鼻喷式疫苗
(FDA Will Evaluate First Self-Administered FluMist Vaccine)
作者：Emily Harris

五、自然：药物发现综述 (2023年11月第22卷)

（一）November 2023 - Volume 22 - Issue 11 (2023年11月第22卷第11期)
https://www.nature.com/nrd/volumes/22/issues/11

NEWS IN BRIEF（新闻简讯）
1.FDA批准第四种JAK抑制剂用于骨髓纤维化
(FDA approves fourth JAK inhibitor for myelofibrosis)
作者：Asher Mullard

RESEARCH HIGHLIGHT（研究亮点）
2.抗精神病药具有双重GPCR结合模式
(Antipsychotic displays dual GPCR binding mode)
作者：Sarah Crunkhorn
3.KRAS抑制剂耐药性中的蛋白稳态重连接
(Rewired proteostasis in KRAS inhibitor resistance)
作者：Alex Eccleston

Review Article（评论文章）
4.用于天然产物药物发现的人工智能
(Artificial intelligence for natural product drug discovery)
作者：Michael W. Mullowney¹, Katherine R. Duncan², Somayah S. Elsayed³, Neha Garg⁴, Justin J. J. van der Hooft⁵, Nathaniel I. Martin⁶, David Meijer⁵, Barbara R. Terlouw⁵, Marnix H. Medema⁵* (1.Duchossois Family Institute, The University of Chicago, USA; 2.Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, UK; 3.Department of Molecular Biotechnology, Institute of Biology, Leiden University, The Netherlands; 4.School of Chemistry and Biochemistry, Center for Microbial Dynamics and Infection, Georgia Institute of Technology, USA; 5.Bioinformatics Group, Wageningen University, The Netherlands; 6.Biological Chemistry Group, Institute of Biology, Leiden University, The Netherlands）

六、自然：免疫学综述 (2023年11月第23卷第11期)

November 2023 - Volume 23 - Issue 11 (2023年11月第23卷第11期)
https://www.nature.com/nri/volumes/23/issues/11

略

七、柳叶刀：呼吸医学 (2023年11月)

November 2023 - Volume 11 - Number 11 (2023年第11卷第11期)
https://www.thelancet.com/journals/lanres/issue/vol11no11/PIIS2213-2600(23)X0011-3

ARTICLES（文章）
1.含AS03佐剂的二价（D614+B.1.351） SARS-CoV-2 重组蛋白疫苗与在成人中的疗效：一项3期、平行、随机、改良的双盲、安慰剂对照试验
(Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial)
作者：Gustavo H Dayan*(Sanofi,USA)

八、英国医学期刊 (2023年11月第383卷第8405-8408期)

（一）04 November 2023 - Volume 383 - Issue 8405 (2023年11月7日第383卷第8405期)
https://www.bmj.com/content/383/8405

Research（研究）
1.初级保健中的多模式干预对减少女性尿路感染二线抗生素处方的影响：平行、整群随机、对照试验
(Effects of a multimodal intervention in primary care to reduce second line antibiotic prescriptions for urinary tract infections in women: parallel, cluster randomised, controlled trial)
作者：Guido Schmiemann, Alexandra Greser* (University of Bremen, Department of Health Services Research, Institute for Public Health and Nursing Research, Germany; University Hospital Wurzburg, Department of General Practice, Germany)
2.改善无并发症的泌尿道感染的抗生素处方
(Improving antibiotic prescribing for uncomplicated UTIs)
作者：Morten Lindbæk* (Antibiotic centre for primary care, Department of general practice, University of Oslo, Norway)
3.吡咯替尼与安慰剂联合曲妥珠单抗和多西他赛作为HER2阳性转移性乳腺癌患者的一线治疗（PHILA）：随机、双盲、多中心、3 期试验
(Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial)
作者：Fei Ma, Binghe Xu* (Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, China)

（二）11 November 2023 - Volume 383 - Issue 8406 (2023年11月11日第383卷第8406期)
https://www.bmj.com/content/383/8406

News（新闻）
1.阿那曲唑：重新利用的药物可以预防数千例乳腺癌病例
(Anastrozole: Repurposed drug could prevent thousands of breast cancer cases)
作者：Elisabeth Mahase

Practice（实践）
2.可持续实践：铁替代疗法的可持续处方
(Sustainable practice: Sustainable prescribing of iron replacement therapy)
作者：Myles Sergeant* (Faculty of Health Sciences, McMaster University, Canada)

（三）18 November 2023 - Volume 383 - Issue 8407 (2023年11月18日第383卷第8407期)
https://www.bmj.com/content/383/8407

News（新闻）
1.研究发现，司美格鲁肽可将主要心血管事件的风险降低 20%
(Semaglutide reduces risk of major cardiovascular events by 20%, finds study)
作者：Jacqui Wise

Practice（实践）
2.质子泵抑制剂
(Proton pump inhibitors)
作者：Danny Jenkins* (Lewisham and Greenwich NHS Trust, UK)
3.抗结核药物性肝损伤
(Anti-tuberculosis drug-induced liver injury)
作者：Wei Shen Lim* (Respiratory Medicine, Nottingham University Hospitals NHS Trust, UK)

（四）25 November 2023 - Volume 383 - Issue 8408 (2023年11月25日第383卷第8408期)
https://www.bmj.com/content/383/8408

Practice（实践）
1.对乙酰氨基酚在成人中的使用
(Paracetamol use in adults)
作者：Thomas M Caparrotta, James W Dear* (Pharmacology, Therapeutics and Toxicology Unit, Centre for Cardiovascular Science, University of Edinburgh, Queen’s Medical Research Institute, UK)

九、自然：医学 (2023年11月第29卷第11期)

November 2023 - Volume 29 - Issue 11 (2023年11月第29卷第11期)
https://www.nature.com/nm/volumes/29/issues/11

CORRESPONDENCE（通信）
1.安慰剂对照在神经退行性疾病临床试验中的作用
(The role of placebo control in clinical trials for neurodegenerative diseases)
作者：Arpan R. Mehta, Siddharthan Chandran*, Suvankar Pal* (ACORD at MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, UK)

Comment（评论）
2.重新思考安慰剂：在罕见肿瘤的临床试验中采用合成对照组
(Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors)
作者：César Serrano* (Department of Medical Oncology, Vall d’Hebron University Hospital, Spain)

Research Briefing（研究简报）
3.建立模型以指导卢旺达对青蒿素耐药性疟疾的药物政策响应
(Modeling to guide drug policy response to artemisinin-resistant malaria in Rwanda)

Article（文章）
4.靶向PD-1和lag -3的双特异性分子tebotelimab在实体瘤和血液系统癌症中的治疗：一项1期试验
(The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial)
作者：Jason J. Luke* (UPMC Hillman Cancer Center and University of Pittsburgh, USA)
5.吉西他滨和顺铂联合纳武利尤单抗作为肌层浸润性膀胱癌的器官保留治疗：一项2期试验
(Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial)
作者：Matthew D. Galsky* (Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, USA)
6.Pleconaril和利巴韦林治疗新发1型糖尿病：一项2期随机试验
(Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial)
作者：Lars Krogvold, Ida Maria Mynarek, Knut Dahl-Jørgensen* (Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Norway)
7.替尔泊肽对超重或肥胖的成年人进行强化生活方式干预后的影响：SURMOUNT-3 3 期试验
(Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial)
作者：Thomas A. Wadden* (Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, USA)
8.Resmetirom 治疗非酒精性脂肪性肝病：一项随机、双盲、安慰剂对照的3期试验
(Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial)
作者：Stephen A. Harrison* (Pinnacle Clinical Research, USA)

十、世界精神病学 (2023年第22卷第3期)

（一）2023 - Volume 22 - Issue 3 (2023年第22卷第3期)
https://onlinelibrary.wiley.com/toc/20515545/2023/22/3

略